In addition, studies show upregulation of TDO2 expression seen in estrogen-receptor-negative but not in estrogen-receptor-positive breast cancer [182], suggesting that expression of TDO2 may be under negative regulatory control by estrogen in this setting. Here, ESR1 is linked to breast cancer.